Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances
<p>Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related mortality worldwide. There were approximately 865000 new cases and 758000 new deaths from HCC globally in 2022, with a projected 77% increase in cases by 2050. Based on landmark clinical trials, such as IMbrave150, H...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2026
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1237170 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|